Last reviewed · How we verify

NCT05688592: PETIFI

Usefulness of PET-CT for Invasive Fungal Infection

Recruiting now Last updated 6 November 2024
What this trial tests

trial testing PET-CT in Invasive Fungal Infections in 224 participants. Currently enrolling.

Timeline
27 April 2023
Primary endpoint
31 October 2024
1 December 2024

Quick facts

Lead sponsorPuerta de Hierro University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment224
Start date27 April 2023
Primary completion31 October 2024
Estimated completion1 December 2024
Sites14 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Puerta de Hierro University Hospital

Who can join

18 and older, any sex, with Invasive Fungal Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are: 1. Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension/staging and monitoring of response/follow-up ? 2. Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Determining the usefulness of systematic <sup>18</sup>F-FDG PET/CT for the management of invasive fungal infection (PETIFI project): a prospective national multicentre cohort study protocol.
    Gutiérrez A, Rodriguez B, Velasquez K, Gutiérrez I, et al · · 2023 · cited 9× · PMID 37355275 · DOI 10.1136/bmjopen-2023-074240
  2. Is neutropenia still the main risk factor for invasive aspergillosis? A contemporary university hospital retrospective cohort of invasive aspergillosis in neutropenic and non-neutropenic patients.
    Gutiérrez-Villanueva A, Diego-Yagüe I, Gutiérrez-Martín I, García-Prieto S, et al · · 2025 · cited 4× · PMID 40281569 · DOI 10.1186/s12941-025-00794-8

Verify or expand the search:

Other trials of PET-CT

Trials testing the same drug.

Other recruiting trials for Invasive Fungal Infections

Currently open trials in the same condition.

Other Puerta de Hierro University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05688592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing